Compare Modified DCF Regimen Versus SOX Regimen Of Efficacy And Safety As First-line Treatment For Advanced Gastric Cancer

Objective:To evaluate the efficacy and safty of modified DCF regimen compared with SOX regimen as first-line treatment for advanced gastric cancer through the retrospecitive study.Method: 1,From January 2012-January 2014,37 patients with pathologically confirmed advanced gastric cancer were enrolled in 1 st Affiliated Hospital of Dalian Medical University.18 patients received modified DCF regimen,12 cases are men and 6 cases are women.Age from30-77 and the median age is 56.8 cases are postoperative recurrence and 10 cases are no surgical treatment;19patients received SOX regimen,12 cases are men and 7 cases are women.Age from34-75 and the median age is 64.9 cases are postoperative recurrence and 10 cases are no surgical treatment;2,Modified DCF regimen was docetaxel 60 mg/m2 iv d1,oxaliplain 100mg/m2 iv d1,capecitabine 1000mg/m2 po d1-14,21 days was a cycle,SOX regimen was tegafur capsules 40 mg per os twice daily on days 1-14(BSA<1.25m2),50 mg os twice daily on days 1-14(1.25m2<BSA<1.5m2),60 mg per os twice daily on days 1-14(BSA>1.5m2)21 days for a cycle.Perfect the relevant examination before chemotherapy and observe adverse reaction,the efficacy was evaluated every 2 cycles.3,The response rate:the disease control rate,clinical date and adverse reactions were performed using X2 method and survival analysis was performed using Kaplan-Meier method and P<0.05 was considered as significant by software of SPSS 19.0.Results: 1,Patients in modified DCF group achieved CR in 0 case,PR in 4 cases,SD in 9cases,PD in 5 cases,RR of 22%,DCR of 72.2%;SOX group achieve CR in 0case,PR in 3cases,SD in 10 cases,PD in 6 cases,RR of 15.8%,DCR of 68.4%,The differences of DCR and RR between the two groups had no significances(P>0.05).2,Evaluation of adverse drug reation: Modified DCF model solutions and SOX treatment of advanced gastric cancer occurrence of adverse reactions can be tolerated,major adverse reactions in bone marrow suppression,gastrointestinal reactions and extremities syndrome,including modified DCF model solution set of high incidence of adverse reactions to the SOX solutions group.3,The follow-up time to February 2016,modified DCF model group live in 5 cases,the SOX group live in 2 cases,modified DCF model solution scheme of survival rate is higher than the SOX group,but the solution set of the last follow-up survival compared differences had no statistical significance(p > 0.05);Modified DCF model group of median progression-free surial was seven months,the SOX solutions group median progression-free surial for four months,two groups of patients with median progression-free surial difference was statistically significant(x~2 = 0.82,p > 0.82);Modified DCF model group of median overall survival was 13 months,SOX group of the median overall survival for eight months,but the two groups of patients with no statistically significant difference in overall survival(x~2 = 6.99,p > 6.99).Conclusion:1.In advanced gastric cancer,the m DCF regimen provide similar efficacy to SOX regimen.2.The adverse reaction of modified DCF regimen and SOX regimen as first-line treatment for advanced gastric cancer can endure,The main events include myelosuppression,Gastrointestinal reaction and the brotherhood of syndrome.Modified DCF regimen high of incidence of adverse reaction than SOX regimen.